Alexa Fluor® 488 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_Alexa488_071805
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) Alexa Fluor® 488 (solid line) or rat IgG2a, κ Alexa Fluor® 488 isotype control (broken line).
  • 53-6.7_Alexa488_071805
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) Alexa Fluor® 488 (solid line) or rat IgG2a, κ Alexa Fluor® 488 isotype control (broken line).
  • 53-6dot7_A488_CD8a_Antibody_2_092021.png
    Paraformaldehyde-fixed (1%), 500 µm-thick mouse thymus section was processed according to the Ce3D™ Tissue Clearing Kit protocol (Cat. No. 427701). The section was costained with anti-mouse CD8a Antibody (clone 53-6.7) Alexa Fluor® 488 at 5 µg/mL (green), anti-mouse CD3ε Antibody (clone 500A2) Alexa Fluor® 594 at 5 µg/mL (blue), and anti-mouse CD68 Antibody (clone FA-11) Alexa Fluor® 647 at 5 µg/mL (magenta). The section was then optically cleared and mounted in a sample chamber. The image was captured with a 10X objective using Zeiss 780 confocal microscope and processed by Imaris image analysis software.
    Watch the video.
Compare all formats See Alexa Fluor® 488 spectral data
Cat # Size Price Quantity Check Availability Save
100726 25 µg 29€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100723 100 µg 58€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
3D IHC - Verified

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. For 3D immunohistochemistry on formalin-fixed tissues, a concentration of 5.0 µg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  2. Moderzynski K, et al. 2016. PLoS Negl Trop Dis. . PubMed
  3. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  4. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  5. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  6. Suzuki K, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:119. PubMed
  7. Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed
  8. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  9. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  10. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  11. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  12. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
  13. Onishi S, et al. 2015. PLoS One. 10:126564. PubMed
  14. Tang B, et al. 2020. Clin Cancer Res. 26:2216. PubMed
  15. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  16. Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed
  17. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  18. Yang H, et al. 2015. Cancer Res . 75: 3812-3822. PubMed
  19. An J, et al. 2022. iScience. 25:103570. PubMed
  20. Bartkowiak T, et al. 2015. Proc Natl Acad Sci U S A. 112: 5290-5299. PubMed
  21. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  22. Xiao Y, et al. 2021. Cancer Cell. 39(3):423-437.e7. PubMed
  23. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  24. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  25. Chen C, et al. 2019. Cell Rep. 29:4200. PubMed
  26. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  27. Yamada T, et al. 2016. J Immunol. 197: 4079 - 4089. PubMed
  28. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  29. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  30. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  31. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  32. Kim S, et al. 2021. Elife. 10:. PubMed
  33. Ma S, et al. 2022. Cell Rep. 38:110520. PubMed
  34. Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed
  35. Mantilla-Rojas C, et al. 2022. Cancers (Basel). 14:. PubMed
  36. Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed
  37. Collins N, et al. 2016. Nat Commun. 7:11514. PubMed
  38. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  39. Sun J, et al. 2020. Cell. 182:734. PubMed
  40. Lee C, et al. 2009. Clin Cancer Res. 2.538888889. PubMed
  41. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  42. Kaddatz H, et al. 2020. Glia. 69:925. PubMed
  43. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  44. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  45. Chen ST et al. 2019. Cell host & microbe. 25(4):602-616 . PubMed
  46. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  47. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  48. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  49. Klose R, et al. 2016. Nat Commun. 7:12528. PubMed
  50. Zhu J et al. 2017. Cell stem cell. 20(3):374-384 . PubMed
  51. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  52. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  53. Simula L, et al. 2022. Mol Oncol. 16:188. PubMed
  54. Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed
  55. Conforti A, et al. 2021. Mol Ther. S1525-0016:00466. PubMed
  56. Simula L, et al. 2020. Cell Death Differ. 27:2749. PubMed
RRID
AB_493423 (BioLegend Cat. No. 100726)
AB_389304 (BioLegend Cat. No. 100723)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 5    Revision Date: 09-20-2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account